Value proposition

Pioneering inhaled medications for cardiovascular conditions

InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF).

Cardiovascular, Inhalation therapy, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Commercialization, Clinical Research, Pre-Clinical Research, and Regulatory Affairs